Is RFL or RLMD more undervalued in 2026?

CirclFi compares Rafael Holdings, Inc. (RFL) and Relmada Therapeutics, Inc. (RLMD) using 13 institutional-grade valuation models. RFL has a Quality of Company score of 4.5/10 while RLMD scores 4.4/10.

Which is a better buy — RFL or RLMD?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do RFL and RLMD valuations compare?

RFL at $1.37 and RLMD at $7.21 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

RFL vs RLMD Valuation Comparison 2026 — Intrinsic Value Analysis

RFL

Pharmaceutical Preparations

Rafael Holdings, Inc.

Quality

4.5

out of 10

Value Trap

DANGER

Price

$1.37

Last close

Models

10/13

Active

RLMD

Pharmaceutical Preparations

Relmada Therapeutics, Inc.

Quality

4.4

out of 10

Value Trap

SAFE

Price

$7.21

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	RFL Fair Value	RFL Upside	RLMD Fair Value	RLMD Upside
Bayesian DCF	Intrinsic	$0.50	-63.4%	$1.99	-72.4%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.80	+31.1%	$1.53	-78.8%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for RFL vs RLMD — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RFL vs RLMD — Which Stock Is More Undervalued?

RFL scores higher with a 4.5/10 quality rating vs RLMD's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Rafael Holdings, Inc. (RFL) and Relmada Therapeutics, Inc. (RLMD) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RFL currently trades at $1.37 with a QOC of 4.5/10, while RLMD trades at $7.21 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).